Needham & Company Downgrades NuVasive (NUVA) to Underperform

Needham & Company downgraded NuVasive (NASDAQ: NUVA) from Hold to Underperform.

Analyst Mike matson says a resurgent MDT puts the company estimates at risk. The analyst comments "We expect NUVA's revenue growth to approach the mid-single digits and its EPS growth to approach the mid-teens and we think this warrants a ~25x P/E multiple putting its fair value at around ~$50/share."

For an analyst ratings summary and ratings history on NuVasive click here. For more ratings news on NuVasive click here.

Shares of NuVasive closed at $61.64 Friday.

You May Also Be Interested In

• GLJ Research Downgrades Fluence Energy Inc. (FLNC) to Hold
• Analog Devices (ADI) PT Raised to $450 at Needham
• Jefferies Downgrades Sunway Healthcare Holdings (SUNMED:MK) to Hold